Gene

SSTR5

somatostatin receptor 5

Explore in graph →CI-GENE-00033870HGNC:11334 ENSG00000162009 NCBI 6755 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SSTR5 Overexpression1
Pasireotide	Neuroendocrine Tumor	Predictive	B	Supports Sensitivity Response	3	accepted	EID10193 Phase II study of pasireotide in metastatic neuroendocrine tumours enrolled 29 patients. Overall median PFS was 11 months (95% CI, 7.6–16 months). High SSTR5 expression (seen in 17/22 samples measured… (full text at CIViC) PMID 25376618 · Cives et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Triple-Negative Breast Cancer (FUSCC, Cell Research 2020) brca_fuscc_2020	Invasive Breast Carcinoma	Ssm	3

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
· Endocr Relat Cancer · 2015 · PMID 25376618 · validated civic_curation pubmed